PBM Disclosure Requirements On Rx Switches Likely To Increase Costs – FTC
Pharmaceutical benefit manager disclosure requirements related to drug switches are likely to increase consumers' drug costs rather than strengthen consumer protections, the Federal Trade Commission said in its review of PBM transparency legislation under consideration in California
You may also be interested in...
CVS Caremark CEO Tom Ryan predicts during the company's second quarter call that "once CBO scores this, [the transparency provision] will not survive."
The Medco injunction reflects the principle that pharmacy benefit management companies should be responsible for the "consequences" of therapeutic interchange, Associate U.S. Attorney James Sheehan said during a May 11 teleconference sponsored by Pharma Audioconferences
The Medco injunction requires the pharmacy benefit management company to disclose the existence of rebate relationships in its communications to clients, physicians and patients